Achaogen company has received the approval of Food and Drugs Administration (FDA) with regard to the marketing authorisation of its highly-efficient Zemdri antibiotic.It will be used when other medicines fail to succeed.
The new extraordinarily strong antibiotic will be used for the treatment of drug-resistant urinary tract infections.What is particularly meant here is related to infections with carbapenem-resistant bacteria that are unofficially called the "nightmare" ones. It is so due to the fact that their presence entails long and expensive hospitalisations, as well as it makes one's recovery processes longer.
In his statement, Blake Wise explains that the drug has been designed in a way securing its high activity during the treatment of infections that are resistant to other antibiotics.
Zemdri is a medicine whose administration relies on intravenous infusions.BARDA agency provided it with financial support.Despite its efficiency, the product also has its side effects ? its use may be harmful in terms of such disorders as kidney damage, the loss of hearing or the neuromuscular blockade.Analysts estimate the sale of the drug to reach the value of USD 500 million at its peak.